3-(benzo[d][1,3]dioxol-5-yl)-5-(3-fluorophenyl)-1H-pyrazole | 1204141-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(benzo[d][1,3]dioxol-5-yl)-5-(3-fluorophenyl)-1H-pyrazole
• 英文别名: 5-(3-fluorophenyl)-3-(3,4-methylenedioxyphenyl)pyrazole；5-(1,3-benzodioxol-5-yl)-3-(3-fluorophenyl)-1H-pyrazole
• CAS: 1204141-71-8
• 化学式: C₁₆H₁₁FN₂O₂
• 分子量: 282.274
• InChiKey: ALKVXDBIUOQMKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(benzo[d][1,3]dioxol-5-yl)-1-(3-fluorophenyl)-3-hydroxyprop-2-en-1-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以84%的产率得到3-(benzo[d][1,3]dioxol-5-yl)-5-(3-fluorophenyl)-1H-pyrazole
  参考文献：
  名称：

  从亲核[18F]氟化物和Stannyl前体制备亲电子放射性卤代18F标签的芳香族氨基酸的实用方法。

  摘要：

  在Scott等人的最新著作中，用[18F] KF制备Cu的亲核放射性氟化用[18F] KF制备18F标记的芳烃的底物范围扩大到了芳基和乙烯基锡烷。基于这些发现，研究了该反应在生产临床相关的正电子发射断层扫描（PET）示踪剂中的潜力。为此，关于不同的反应参数，重新评估了使用三甲基（苯基）锡作为模型底物的Cu介导的放射性氟脱锡。所得的标记方案应用于RCC中16-88％的不同富电子，-中性和-差的芳基锡烷基底物的18F氟化反应。此外，该方法用于从常规用于亲电子放射性卤化反应的额外的N-Boc保护的市售苯乙烯基前体合成18F标记的芳香族氨基酸。最后，自动合成6- [18F]氟-lm-酪氨酸（6- [18F] FMT），2- [18F]氟-1-酪氨酸（2- [18F] F-Tyr），6- [18F建立了]氟-1,3,4-二羟基苯丙氨酸（6- [18F] FDOPA）和3-O-甲基-6- [18F] FDOPA（[18F]

  DOI：

  10.3390/molecules22122231

文献信息

• NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Giese Armin

  公开号：US20110293520A1

  公开（公告）日：2011-12-01

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).

  本发明涉及一种由公式（E）表示的化合物。本发明还涉及一种由公式（E）表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外，本发明涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式（E）中，X、Y和L分别独立地从—C（R1）（R2）—、—C（R3）═、—N（R4）—、—N═、—N+（R5）═、—O—和—S—中非定向选择；M和Z分别独立地从公式（I）和公式（II）中非定向选择。
• DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：US20160185730A1

  公开（公告）日：2016-06-30

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外，本发明还涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
• Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2687513A1

  公开（公告）日：2014-01-22

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
• Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN

  公开号：US10435373B2

  公开（公告）日：2019-10-08

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
• Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US11180518B2

  公开（公告）日：2021-11-23

  The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.

  本发明涉及一种由式（E）代表的化合物，它可用于治疗或预防黑色素瘤。